University Hospital Zagreb, Psychiatric Clinic, Kišpatićeva Street, Zagreb, Croatia.
Psychiatry Res. 2011 Aug 30;189(1):21-5. doi: 10.1016/j.psychres.2010.11.021. Epub 2011 Jan 7.
There is accumulating evidence for an increased prevalence of metabolic syndrome (MetS) in bipolar patients, which is comparable to the prevalence of MetS in patients with schizophrenia. Hyperhomocysteinaemia has emerged as an independent and graded risk factor for the development of cardiovascular disease (CVD), which is, at the same time, the primary clinical outcome of MetS. The aim of this study was to ascertain if the presence of MetS was associated with hyperhomocysteinaemia in patients with bipolar disorder (N=36) and schizophrenia (N=46) treated with second-generation antipsychotics (SGA). MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III) criteria and the cut-off point for hyperhomocysteinaemia was set up at 15 μmoll(-1). Results of the study indicated that the presence of the MetS is statistically significantly associated with the elevated serum homocysteine in all participants. As hyperhomocysteinaemia has emerged as an independent risk factor for psychiatric disorder and CVD, it could be useful to include fasting homocysteine serum determination in the diagnostic panels of psychiatric patients to obtain a better assessment of their metabolic risk profile.
越来越多的证据表明，双相情感障碍患者的代谢综合征（MetS）患病率增加，这与精神分裂症患者的 MetS 患病率相当。高同型半胱氨酸血症已成为心血管疾病（CVD）发展的一个独立且分级的危险因素，同时也是 MetS 的主要临床转归。本研究旨在确定接受第二代抗精神病药物（SGA）治疗的双相情感障碍（N=36）和精神分裂症（N=46）患者中，MetS 是否与高同型半胱氨酸血症有关。MetS 根据国家胆固醇教育计划成人治疗专家组 III（NCEP ATP-III）标准定义，高同型半胱氨酸血症的截断值设定为 15 μmol/L。研究结果表明，在所有参与者中，MetS 的存在与血清同型半胱氨酸升高呈统计学显著相关。由于高同型半胱氨酸血症已成为精神障碍和 CVD 的独立危险因素，因此在精神科患者的诊断方案中纳入空腹同型半胱氨酸血清测定可能有助于更好地评估其代谢风险状况。
